1. Home
  2. DFLI vs CALC Comparison

DFLI vs CALC Comparison

Compare DFLI & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dragonfly Energy Holdings Corp. (NV)

DFLI

Dragonfly Energy Holdings Corp. (NV)

HOLD

Current Price

$1.16

Market Cap

18.8M

Sector

Technology

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$2.35

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFLI
CALC
Founded
2020
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8M
19.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DFLI
CALC
Price
$1.16
$2.35
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$3.25
$10.00
AVG Volume (30 Days)
345.5K
302.4K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,630,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$51.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.77
N/A
52 Week Low
$0.26
$0.46
52 Week High
$5.15
$7.20

Technical Indicators

Market Signals
Indicator
DFLI
CALC
Relative Strength Index (RSI) 39.81 32.28
Support Level $1.11 N/A
Resistance Level $1.46 $0.73
Average True Range (ATR) 0.07 0.05
MACD 0.01 -0.01
Stochastic Oscillator 24.97 0.18

Price Performance

Historical Comparison
DFLI
CALC

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: